Email: cspc@cspc.cn

Contact Us

CSPC Holdings Company Limited

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

October 24, 2025

a251024_01(1).jpg

Previous: VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA

Next: VOLUNTARY ANNOUNCEMENT - JSKN003 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED COLORECTAL

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号